VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the fourth quarter and year ended December 31, 2015. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Recent operational highlights
Aura-LV (AURA) Phase 2b clinical trial update- Patient enrollment completed
